Homology Medicines, Inc.: insider trades · United States · SEC (Form 4)

About Homology Medicines, Inc.

Homology Medicines, Inc. is a U.S.-based genetic medicines company historically listed on NASDAQ under ticker FIXX. For investors, the key point is that the company underwent a major corporate transformation: on March 25, 2024, Homology completed its merger with Q32 Bio, after which Homology changed its name to Q32 Bio, Inc., and the legacy Homology business was reorganized within the combined structure. As a result, FIXX should be viewed through both its historical biotech identity and the post-merger entity that emerged from the transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661998/000095017025036823/qttb-20241231.htm?utm_source=openai)) Historically, Homology was a clinical-stage genetic medicines company focused on rare diseases with significant unmet medical need. Its core mission was to develop one-time gene therapy and gene editing treatments aimed at addressing the underlying cause of disease, rather than merely managing symptoms. The company’s principal offices were in Bedford, Massachusetts, United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661998/000095017023006995/fixx-20221231.htm?utm_source=openai)) From a technology standpoint, Homology’s differentiator was its proprietary AAVHSC platform, a family of adeno-associated virus vectors derived from human stem cells. Management positioned this platform as a foundation for in vivo delivery of one-time genetic medicines, including gene therapy and nuclease-free gene editing approaches. This placed the company in a highly specialized competitive landscape alongside a small set of gene therapy and genome-editing developers, where technical execution, clinical safety, and capital access are critical. ([homologymedicines.com](https://homologymedicines.com/images/uploads/pdf/HomologyCorporateProfile_July2022.pdf?utm_source=openai)) The company’s historical pipeline targeted rare genetic and metabolic disorders, including phenylketonuria (PKU), Hunter syndrome (MPS II), and discovery-stage programs in other rare-disease areas. In investment terms, Homology was a pre-commercial biotech with limited or no product revenue, and its value proposition depended on advancing clinical programs, securing funding, and demonstrating a durable platform advantage. ([homologymedicines.com](https://homologymedicines.com/images/uploads/pdf/HomologyCorporateProfile_July2022.pdf?utm_source=openai)) The most important recent event was the March 2024 merger with Q32 Bio. That transaction materially changed the equity story: it reset the corporate structure, altered the company name, and brought a new strategic configuration for public-market investors to assess. SEC filings after the merger confirm the continued regulatory reporting around the combined business, which means FIXX investors should monitor not only historical Homology disclosures but also post-merger corporate actions, financing activity, and insider transactions filed on Form 4. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661998/000095017025036823/qttb-20241231.htm?utm_source=openai)) In short, FIXX represents a U.S. NASDAQ-listed biotechnology story rooted in genetic medicine, originally built in Bedford, Massachusetts, and reshaped by a transformative merger in 2024 that materially changed the company’s risk profile, strategy, and market interpretation.